Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | MPL | P40238 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23610348 | 0.84 | ALDH1A1 (0.41) | HTR6DRD2CYP1A2ALDH1A1MAPT | |
| SCHEMBL23618144 | 0.84 | MPL (0.48) | HTR6DRD2MPLSMN1; SMN2CYP1A2 | |
| SCHEMBL23610350 | 0.84 | MAPT (0.45) | HTR6DRD2SMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL6385170 | 0.83 | HTR6 (0.55) | HTR6DRD2MPLSMN1; SMN2ALDH1A1 | |
| SCHEMBL28902429 | 0.81 | MPL (0.55) | HTR6DRD2MPLSMN1; SMN2CYP1A2 | |
| SCHEMBL29428919 | 0.75 | ADORA1 (0.51) | MPLSMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL30256985 | 0.75 | MYC (0.56) | HTR6DRD2MPLSMN1; SMN2ALDH1A1 | |
| SCHEMBL24090368 | 0.75 | ADORA1 (0.55) | MPLSMN1; SMN2CYP1A2ALDH1A1MAPT | |
| SCHEMBL31642748 | 0.75 | MPL (0.46) | HTR6DRD2MPLSMN1; SMN2ALDH1A1 | |
| SCHEMBL330423 | 0.73 | SMN1; SMN2 (0.64) | MPLSMN1; SMN2CYP1A2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390333-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-11-28 | — | — | US | disclosed |
| US-11974988-B2 | Neuroprotective compositions and methods of using the same | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-05-07 | — | — | US | disclosed |
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2021-07-08 | — | — | US | disclosed |
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | GAP43, NLN, SMN1; SMN2 | HTR6 1222/4885DRD2 1549/4885MPL 4766/4885 |
| US-11974988-B2 | Neuroprotective compositions and methods of using the same | GAP43, NLN, SMN1; SMN2 | HTR6 1222/4885DRD2 1549/4885MPL 4766/4885 |
| US-20240390333-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | GAP43, NLN, SMN1; SMN2 | HTR6 1222/4885DRD2 1549/4885MPL 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.